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Little is known about variation in surveillance practices following the diagnosis of invasive melanoma. The
objective of this study was to characterize geographic, patient, and tumor variation in the use of follow-up
surveillance testing in patients with local or regional stage melanoma. A cohort of Medicare beneﬁciaries X65 y
diagnosed with invasive melanoma during 1992 to 1996 living in a Surveillance, Epidemiology, and End Results
registry area was studied. Outpatient and inpatient Medicare claims 3 mo following diagnosis were examined for up
to 2 y for surveillance procedures of interest. Use of chest X-ray, chest computed tomography scan, abdominal and/
or pelvic computed tomography scan, abdominal ultrasound, head computed tomography scan, head magnetic
resonance imaging, laboratory testing, and skin examinations were compared between patient groups and
geographic regions. A total of 3389 patients were identiﬁed for the analysis. Surveillance testing was relatively
common, ranging from 13% for abdominal ultrasound to 80% for laboratory testing. Follow-up skin examinations
were performed in 70% to 90% of patients. The use of most surveillance procedures was associated (po0.01) with
younger age, male gender, regional stage tumors, and geographical area, with up to 2-fold differences observed. In
contrast, there was much less variability in the receipt of skin examinations. Further studies are needed to
determine the etiology and impact of such disparities, and the inﬂuence of surveillance procedures on morbidity
and mortality.
Key words: cancer/clinical practice variation/follow-up testing/health services research/physician’s practice
patterns.
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In 2003, melanoma is expected to be the fifth most common
cancer in men and seventh most common cancer in women
in the United States, with an estimated 54,000 new cases.
Although more than 90% of these melanomas are diag-
nosed prior to the development of distant metastasis and
thus potentially curable (Jemal et al, 2003) there is an
estimated 5% to 30% risk of recurrence after excision (Poo-
Hwu et al, 1999). Moreover, an estimated 2% to 5% of
patients will develop an additional primary melanoma
(Beardmore and Davis, 1975; Cascinelli et al, 1975; Veronesi
et al, 1976; Kang et al, 1992; Slingluff et al, 1993; Giles et al,
1995; Brobeil et al, 1997; Levi et al, 1997; Johnson et al,
1998). The risk of recurrence and secondary primary tumors
together with the fact that melanoma recurrences may arise
10 or more years following diagnosis (Koh et al, 1984;
Crowley and Seigler, 1990; McEwan et al, 1990; Pearlman
et al, 1992; Slingluff et al, 1992; Tahery and Moy, 1993; Tsao
et al, 1997) provides a rationale for regular follow-up visits
as well as routine laboratory and radiographic tests. The
benefit of routine surveillance is the detection of asympto-
matic melanoma at a stage where therapy is more effective
than in the absence of surveillance (Richert et al, 1998;
Dicker et al, 1999).
Several different surveillance schedules that are based
on recurrence or detection patterns or through consensus
panels of experts have been recommended for patients with
a history of melanoma (McCarthy et al, 1988; Reintgen et al,
1992; Martini et al, 1994; Romero et al, 1994; Shumate
et al, 1995; Weiss et al, 1995; Houghton et al, 1998; Dicker
et al, 1999; Poo-Hwu et al, 1999). Whereas the majority of
these reports have proposed relatively frequent follow-up
for melanomas of worse prognosis, more intensive follow-
up during the first few years, and lifetime surveillance of
melanoma survivors, the actual follow-up intervals and use
of surveillance procedures vary considerably. Most recently,
the American Academy of Dermatology (AAD) has pub-
lished a statement regarding melanoma surveillance as part
of broader guidelines on the care for primary cutaneous
melanoma (Sober et al, 2001). This statement was the first
such recommendation to meet the standards of the National
Abbreviations: LDH, lactic dehydrogenase; SEER, Surveillance,
Epidemiology and End Result Medicare database.
1Tables 4, 6, and appendix can be found at http://www.
blackwellpublishing.com/products/journals/suppmat/jid/jid22238/
jid22238sm.htm
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Guideline Clearinghouse (NGC) sponsored by the Agency
for Healthcare Research and Quality (AHRQ) and American
Medical Association (AMA). While stating that there is no
evidence to support a specific follow-up interval schedule,
this taskforce recommended follow-up in some situations,
including patient education, examination of the skin, and
laboratory/radiologic examination between one and four
times per year for the first 2 y after diagnosis and one to two
times per year thereafter. The taskforce also stated that
routine laboratory tests and imaging tests are ‘‘not required
in asymptomatic patients with primary cutaneous melano-
map4 mm in depth for initial staging or routine follow-up’’,
but that routine interval history and physical examination
should direct the need for laboratory and imaging tests. No
recommendations were made for melanoma greater than
4 mm depth.
Whereas recent prospective evidence suggests that
close follow-up of patients diagnosed with melanoma is
associated with thinner second primary lesions relative to
the original malignancy, no randomized study has been
performed to test whether these differences in lesion
thickness were due to the surveillance, patient education,
or other factors (DiFronzo et al, 2001). Moreover, it is
unknown whether surveillance testing improves patient
survival, and if so, which surveillance procedures, at what
intervals, for how long, and at what reasonable cost
comprises appropriate care. False positives resulting from
surveillance may also lead to patient anxiety and risk
associated with follow-up testing. In the absence of
definitive evidence favoring one approach over another
various follow-up schedules have been proposed in the
literature, ranging from recommending only clinical exam-
inations, to intensive schedules incorporating sophisticated
laboratory testing and medical imaging (Shumate et al,
1995; Ross, 1996; Huang et al, 1998; Poo-Hwu et al, 1999;
Hofmann et al, 2002; Garbe et al, 2003).
Theories of geographical variation suggest that ambi-
guity, a lack of evidence, and a lack of consensus are
determinants of provider-driven geographical variation in
medical care (Wennberg and Gittelsohn, 1973, 1982;
Wennberg et al, 1982). On a national level, these differences
are thought to contribute to variation in costs as well as
health outcomes (Chassin and Galvin, 1998; Becher and
Chassin, 2001). Using a national-level tumor registry linked
to health claims, we hypothesized that given the lack of
consensus on surveillance regimens, significant geographic
variation in surveillance practices would be observed. We
also proposed that significant variation for patient gender
and age would be seen, in accordance with patterns seen
for other cancers (Hillner et al, 1996). In addition, it was
hypothesized that patients with more advanced tumor
stage, and greater Breslow depth (tumor thickness in
millimeters) are more likely to undergo surveillance proce-
dures because clinicians would be more likely to follow-up
those patients with the highest risk of recurrence.
Results
We identified 11,293 patients from 1992 to 1996 who were
diagnosed with melanoma. Patients were excluded for the
following reasons: In situ melanoma (n¼ 3952), enrollment
in a managed care program that processes its own claims
(n¼1501), lack of enrollment in both part A and part B
Medicare (n¼ 468), patients with distant or unknown stage
cancer (n¼ 708), patients with previous cancer diagnosis
(n¼1128), and patients who were censored during the first
3 mo following diagnosis, before the surveillance period
began (n¼149). The remaining 3387 patients were included
in the analysis. Among this cohort, 2607 (62%) survived for
at least 2 y of follow-up or the end of December 1998, 235
(7%) were censored due to diagnosis with a second cancer
(of these 28% of these were second melanoma primaries),
and 545 (16%) were censored due to death.
Characteristics of the cohort are described in Table I.
Fifty-seven percent of the cohort was male, 98% was
Caucasian, and 50% was at least 75 y of age. Eighty-five
percent of tumors were diagnosed as local stage, with the
remainder of regional stage. Eighty-nine percent of the
cohort was followed for at least 12 mo and 74% of
the cohort was followed without being censored for the full
24 mo.
Table II displays the percentage of patients receiving at
least one surveillance procedure of interest at the end of 2 y
of surveillance using Kaplan–Meier estimates, and the
median time to the first test. The most common surveillance
tests performed were CBC (80%), liver enzymes or lactic
dehydrogenase (LDH, 78%), and CXR (71%). CT scans
were performed in 13% (chest CT) and 17% (abdominal/
pelvic CT) of the patients. Head MRI was the least common,
with 8% of patients undergoing this procedure. The more
specific measure of a follow-up visit indicated that at least
70% of patients had visits where their skin was examined.
The more sensitive measure suggested that potentially
more than 90% had such follow-up visits.
Differences in the use of surveillance procedures for
patient and clinical characteristics is displayed in Table III.
For most tests, gender was significantly associated
(po0.01) with receipt of surveillance, with higher values
observed in men than in women. There was a trend for older
aged patients to receive less surveillance testing, with the
exception of head CT and CBC, which were more common.
An exception to these findings was skin examinations,
which is the most uncontroversial and uniformly recom-
mended surveillance procedure. Skin examination surveil-
lance generally remained uniformly high across patient
characteristics. Surveillance was also significantly asso-
ciated with regional stage tumors (compared with local
stage), and thicker Breslow depth of the primary melanoma.
Geographic differences in the use of surveillance
procedures based on Kaplan–Meier analysis and the Log-
Rank test are displayed in Table IV. With the exception of
chest CT, the use of all procedures varied between SEER
registries. For the test assessing for overall differences in
the distribution of procedures with median level of surveil-
lance incidence ranking, a statistically significant departure
from expected incidence across the SEER regions
(po0.001) was found. As this overall result was significant,
we tested to find which regions had greater or fewer
surveillance procedures with above (or below) median
incidence than can be explained by chance. We found
one region (K) where all 10 surveillance procedures were
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performed with above median incidence (p¼0.003). Two
regions (B, C) had above median use of testing for nine of
10 tests performed (p¼ 0.0217) and three regions (D, E, J)
had below median number of surveillance procedures (two
of 10) (p¼ 0.0293).
In the multivariate analysis controlling for patient char-
acteristics, tumor characteristics, geographical area, pov-
erty, and comorbidities (Table V), almost all surveillance
procedures were more frequently performed in patients
with regional stage melanoma, thicker Breslow depth of
the primary melanoma, or both. Significant differences in
the use of selected procedures persisted in younger
patients and male patients.
In a multivariate analysis controlling for potentially
confounding factors, there was significant (po0.01) varia-
tion in the use of CXR, head CT, liver/LDH enzymes, CBC,
and the sensitive and specific measures of follow-up visits.
With few exceptions, we found no significant variation
across SEER regions in surveillance for chest CT, abdominal
and/or pelvic CT, abdominal US, or head MRI (Table VI).
Discussion
In contrast to breast and colorectal cancer (Rosselli Del
Turco et al, 1994; Schoemaker et al, 1998) there has been
no randomized trial to date examining the effect of
surveillance practices on long-term survival or other
measurable outcomes in melanoma. Whereas second
primaries tend to be thinner than the original (Moseley et al,
1979; Kang et al, 1992; Brobeil et al, 1997; DiFronzo et al,
2001) in high-risk patients undergoing surveillance for
melanoma, the extent to which this difference is attributable
to surveillance practices is not certain, as the great majority
of recurrences are detected by patients or history and
physical examination (Basseres et al, 1995; Shumate et al,
1995; Ross, 1996). Poo-Hwu et al (1999) reviewed the
records of 373 patients on frequent follow-up interval visits,
Table I. Patient characteristics of 3387 patients diagnosed with
invasive melanoma
Variable n (%)
Gender
Male 1938 (57.22)
Female 1449 (42.78)
Age group
65–69 844 (24.92)
70–74 882 (26.04)
75–79 754 (22.26)
80–84 489 (14.44)
85þ 418 (12.34)
Stage
Local 2894 (85.44)
Regional 493 (14.56)
Breslow depth increments
p1 mm Breslow depth 1671 (49.34)
1.01–2.00 mm Breslow depth 531 (15.68)
2.01–4.00 mm Breslow depth 453 (13.37)
44.00 mm Breslow depth 233 (6.88)
Breslow depth unknown 499 (14.73)
SEER geographic region
A 240 (7.09)
B 601 (17.74)
C 491 (14.50)
D 67 (1.98)
E 443 (13.08)
F 139 (4.10)
G 363 (10.72)
H 201 (5.93)
I 223 (6.58)
J 165 (4.87)
K 454 (13.40)
Comorbidity
No comorbidities 1993 (58.84)
1 comorbidity 854 (25.21)
2þ comorbidities 540 (15.94)
AMedian follow-up for all patients was 24 months.
Table II. Crude frequency of surveillance procedures for
n¼ 3387 patients diagnosed with invasive melanoma
Surveillance
measure
Frequency by
end of 2 y
Mean time to
ﬁrst test (mo)
CXR 70.6 6
Chest CT 13.2 9
Abd/pelvic CT 16.5 9
Abdominal US 15.0 10
Head CT 15.3 10
Head MRI 7.6 10
Enzyme 77.6 5
CBC 79.8 4
Specific skin examination 69.8 2
Sensitive skin examination 90.3 1
The percentages reported correspond to the proportion of patients
who received at least one such test at the end of 2 y of surveillance
follow-up, using Kaplan–Meier estimates, which take into account
variable follow-up time. Mean time to first test indicates for the patients
who were tested, the average time to the first test for the complete
follow-up period varying from 0.5 to 24.5 mo for each patient. Mean
rather than median time was used because the distribution of censoring
did not permit computing median for all cases. Mean values tend to be
inflated due to the presence of outlier surveillance procedures performed
late in the follow-up period. Abd/pelvic CT refers to abdominal and/or
pelvic CT. Enzym refers to both liver enzymes and/or LDH surveillance
measures.
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and found that half of locoregional recurrences were
detected by patients, whereas more than half of distant
metastases were detected by physicians (mostly by history
or physical). These authors reported a survival difference
between symptomatic and asymptomatic recurrences, but
it has been questioned whether these differences represent
lead time bias (Chartier and Bigby, 2000) because similar
studies have found higher percentages of recurrences
found by patients, but no such survival difference (Baughan
et al, 1993; Shumate et al, 1995). In contrast, another recent
study (Garbe et al, 2003) found that 21% of recurrences
were discovered by lymph node sonography rather than
physical examination, with 48% of these occurrences
classified as ‘‘early detection’’ associated with improved
survival. This last report, whereas not conclusive, is
suggestive of the potential for some surveillance tests to
be effective at improving recurrent melanoma outcomes.
In light of uncertainty regarding the efficacy of laboratory
testing and medical imaging in improving the prognosis of
recurrence or second primaries in patients with a history of
melanoma, it is not surprising that we found more variation
in surveillance practices than can be explained by chance.
Surveillance testing was relatively common in our popula-
tion at the end of 2 y of follow-up, ranging from about 15%
for abdominal US and CT scans to 88% for liver enzymes or
LDH. Follow-up visits suggestive that the skin was
examined was 70% for the higher specificity algorithm,
and about 90% for the more sensitive algorithm. These
results are consistent with skin examination and history
being the most common surveillance procedures recom-
mended, and laboratory testing being the most common
routine surveillance tests recommended. The results of our
study are consistent with a survey of members of the
American Society of Plastic and Reconstructive Surgeons
(ASPRS), which found that there was considerable variation
in self-reported surveillance intensity (Virgo et al, 2000). In
another study based on the same ASPRS survey, the
authors noted that intensity of melanoma surveillance varied
by tumor stage, although not to the extent as they expected
(Johnson et al, 2001).
Variation in surveillance by geographical region, whereas
not explainable by clinical, tumor, or patient variables,
including poverty, may be accounted for by a number of
unmeasured factors. First, whereas our sample was
restricted to nonmanaged care participants, it is also
possible that persons not enrolled in Medicare managed
care plans may receive more surveillance by virtue of living
in a high managed care geographic area (Baker, 1999). Also,
whereas our analysis has controlled for poverty, factors
associated with access to healthcare may vary by region
and thus influence the probability that the patient has
received various forms of surveillance care. Differences in
patient preferences may also vary by region and influence
follow-up care received, although we have no reason to
believe so in our study.
Our model found a trend for variation by age, with older
persons in the cohort being less likely to receive certain
procedures than their younger counterparts. This finding is
consistent with other studies that have found older patients
are less likely to receive extensive workups, such as
invasive procedures and imaging studies (Ayanian and
Guadagnoli, 1996; Cooper et al, 1999; Hodgson et al, 2001).
Men were significantly more likely to receive certain
surveillance procedures relative to women. One possible
explanation is that men receive more intensive surveillance
because physicians are aware that prognosis in men tends
to be worse than for women. Under this hypothesis,
differences in surveillance procedure frequency between
men and women may represent overcompensation by
providers as our analysis controlled for important measures
of prognosis including stage and Breslow depth. It is also
possible that gender differences in surveillance may be
attributed to patient preferences in routine care. Finally, it is
possible that gender differences in surveillance are attribu-
table to residual confounding by comorbidities, as older
men are typically sicker and thus are more likely to receive
surveillance procedures examined for reasons besides
melanoma surveillance.
As expected, all surveillance imaging and laboratory
tests were more common for regional versus local stage,
and for greater relative to lesser Breslow depth. Such
‘‘variation’’ is expected and consistent with the natural
history of melanoma, where patient subgroups most likely
to recur should be followed most closely.
This study has several relevant limitations. First, because
our study is based on claims data, we cannot determine
whether a given procedure was performed for routine
surveillance, for the evaluation of suspected recurrence,
or for unrelated medical problems. We minimized the
potential for such nonsurveillance confounding by excluding
patients with previous cancer; however, censoring patient
data at the diagnosis of new cancer primaries, by excluding
patients who died within the first 3 mo after diagnosis, and
by only considering surveillance procedures performed
during the first 2 y of follow-up. In addition, we adjusted
for patient comorbidities to control for the influence of
nonmelanoma health conditions on variation in surveillance
procedures. A second limitation was that this study involved
secondary analysis of Medicare administrative data codes,
which are collected for billing rather than research
purposes. Whereas we have found Medicare claims to be
90% sensitive to melanoma diagnosis relative to a Gold
Standard by SEER (unpublished data), information is
lacking on the accuracy of the surveillance procedures
analyzed for this study. Systematic differences in coding
practice or completeness of the claims could potentially
bias the evaluation of surveillance variation, but such
potential was minimized by restricting the analysis to age-
entitled Medicare beneficiaries enrolled in both part A and
part B Medicare during the duration of the study. Third,
because this study was restricted to age-entitled Medicare
beneficiaries over 64 y of age, our results may not be
generalizable to younger populations, which are more likely
to develop melanoma. The risk of melanoma increases with
age, however, and over 37% of melanoma cases are in
reported patients over 65 (Ries et al, 2003). Finally,
this study did not examine the impact of procedures
on long-term survival for this cohort, because such an
analysis would have been subject to verification bias,
where procedures may be performed due to unmeasured
prognostic factors and thus be associated with poorer
survival.
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Consistent with other cancer studies characterizing
national variation in surveillance practices (Deleyiannis
et al, 1997; Cooper et al, 1999; Knopf et al, 2001), we
considered patients to have underwent surveillance if they
received at least one surveillance test during the designated
surveillance window (3 mo postdiagnosis to 24 mo
postdiagnosis). This definition was favored because we
were interested in comparing groups of patients who
received any surveillance with those who received none,
rather comparing different frequencies of surveillance. An
alternative approach would have involved using a more
stringent definition of surveillance that requires at least two,
three, or more surveillance procedures. We note in this
study, however, that this restriction would have required
consideration of surveillance procedures beyond 24 mo
postdiagnosis (as some procedures are performed on an
annual basis). Extending the surveillance window beyond
this period thus would also have decreased the probability
that what we are measuring was truly due to surveillance
(the greater the time between diagnosis and date of the
surveillance, the less likely the procedure was performed to
follow-up on the melanoma), and substantially reduced the
information available for study (over 20% of the uncensored
cohort would be censored immediately beyond 2 y of
follow-up, and over 40% beyond 3 y, due to the dynamic
cohort design incorporating cases diagnosed from 1992 to
1996).
Another alternative to our analytical approach would
have been to require melanoma ICD-9-CM diagnostic
codes directly linked to surveillance procedures for them
to be dubbed surveillance. Whereas this approach may
increase the specificity of the surveillance procedures, the
concern is that this method has not been validated for
medical imaging and laboratory testing codes, which may
results in poor and variable sensitivity and negative
predictive value secondary to the use of linked nonmela-
noma diagnosis for reimbursement purposes. Accurate
diagnostic coding for asymptomatic melanoma surveillance
procedures is particularly problematic, where there is
presently little evidence for the benefit of imaging and
laboratory test follow-up and thus reluctance by insurers to
reimburse them. Future work should explore the benefits
and limitations of utilizing such alternative measures of
surveillance.
In this study examining 3391 Medicare beneficiaries
diagnosed with local or regional stage invasive melanoma,
we found significant variation in the use of follow-up tests
but relatively consistent follow-up visits where the skin was
likely examined. Whereas differences in follow-up variation
by stage and Breslow depth are appropriate, further
prospective studies are needed to verify these observa-
tions, and explore the underlying causes for differences in
surveillance practices observed by sex, age, and across
region that are not explained by tumor prognosis and
comorbid conditions.
Materials and Methods
Data sources and study subjects The cohort for this analysis
was derived from the linked Surveillance, Epidemiology, and End-
Result (SEER)-Medicare database, which was created in 1992
through collaboration of the National Cancer Institute (NCI) and the
Centers for Medicare and Medicare Services (CMS) to answer
research questions for the study of cancer costs, services,
variation, and outcomes (Potosky et al, 1993), and has been used
to examine a variety of cancer-related health services questions
(Moulton, 1998). Because SEER-Medicare data have been
stripped of all personal identifiers, this study did not require IRB
approval. Whereas SEER is the NCI’s national tumor registry in the
United States, Medicare data consist of health insurance claims for
97% of the US population 65 y of age and older (Warren et al,
2002). As of 1992, the population-based SEER tumor registry
included the geographic area corresponding to 14% of the US
population covering the following geographical areas: the states of
Connecticut, Iowa, New Mexico, and Utah, the metropolitan areas
of Detroit, Michigan, San Francisco-Oakland, Los Angeles County,
and San Jose-Monterey area, 10 rural counties in Georgia, 13
counties in the Seattle-Puget Sound area of Washington state,
Hawaii, and American Indians residing in Arizona. For the linked
database, records of patients X65 y who resided in SEER areas
were successfully linked to Medicare beneficiaries through the
record linkage deterministic algorithm (Potosky et al, 1993). A total
of 94% of potentially eligible cases were successfully linked. The
result was a database with detailed tumor staging and date of
diagnosis from SEER, and long-term diagnosis, therapeutic
procedures, cost, utilization, and comorbidity information from
Medicare (Potosky et al, 1993).
For this analysis, date of diagnosis, age, gender, stage of
disease (local, regional, distant, or unstaged), and Breslow depth
(depth in millimeters) of melanoma was obtained from the SEER
Patient Entitlement and Diagnosis Summary File (PEDSF) from
1992 to 1996 in the linked SEER-Medicare database. Part A
Medicare claims includes inpatient hospital insurance claims.
These files were obtained for 1991 to 1998, and derived from
Medicare Provider Analysis and Review (MEDPAR) files. Part B
Medicare medical insurance includes claims related to outpatient
and provider billing. These files were obtained for 1991 to 1998
from Outpatient Standard Analytic Files (SAF) for outpatient
hospital and ambulatory surgery center procedures, and from
National Claims History (NCH) for physician and other outpatient
noninstitutional claims.
As Medicare is primarily an age-dependent entitlement, the
analysis was restricted to Medicare beneficiaries over 64 y in age.
Patients were excluded from the analysis for the following reasons:
patients with in situ melanoma (due to potential underreporting,
Seiffert, 1992), unknown date of diagnosis, lack of enrollment in
both part A and part B Medicare, patients enrolled in managed
care who process their own claims at any time, because Medicare
data are incomplete for this group, and patients with distant or
unknown stage disease. Patients with previous cancer were
excluded to ensure that surveillance was performed for the
melanoma under study, and patients who died or were censored
before the start of the surveillance period at 3 mo postdiagnosis
were also excluded from analysis. Additionally, censoring of patient
records was performed at the first of any of the following events: 2
y of follow-up, date of death, diagnosis with a second cancer
primary, or end of the follow-up period on December 31, 1998. The
analysis was restricted to only 2 y of follow-up because laboratory
and imaging surveillance procedures performed beyond this
window are more likely to be due to patient symptoms or other
causes independent of routine follow-up.
Measures Patient-level demographic and clinical variables in-
cluded age, gender, stage of disease at diagnosis (local or
regional), Breslow depth, and vital status until the end of 1996. A
proxy variable for individual’s socioeconomic status, the race-
specific percent of individuals living below federal poverty level
from the patient’s census-tract (or census block when unavailable)
was also included.
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To adjust measures of surveillance for general health status, a
previously validated modification of the Charlson comorbidity Index
was used (Charlson et al, 1987; Deyo et al, 1992), which was
stratified into patients with 0, 1, or 2 or more comorbidities. This
index utilized primary or secondary diagnosis International Classi-
fication of Disease 9th Revision Clinical Modification (ICD-9-CM)
codes during the year prior to the melanoma diagnosis from part A
and part B Medicare claims. Because this study is based on a
cohort of melanoma patients, only noncancer comorbidities were
included in this index: myocardial infarction, congestive heart
failure, peripheral vascular disease, cerebrovascular disease,
dementia, chronic pulmonary disease, rheumatologic disease,
peptic ulcer disease, diabetes, diabetes with chronic complications,
hemiplegia or paraplegia, renal disease, mild, moderate or severe
liver disease, and acquired immunodeficiency syndrome (AIDS).
Inpatient, outpatient, and physician/supplier claims were
examined for the presence or absence of follow-up procedures
from 3 mo after diagnosis (designated the start of the surveillance
period) to the end of the follow-up period on December 31, or the
first censoring event which includes the first occurrence of the
following: 2 y of follow-up, diagnosis with a second cancer, or
death. The 3 mo window was used to avoid including procedures
performed for preoperative evaluation, postsurgical follow-up, or
because of postoperative complications. All follow-up was
measured in months, and assumed each event would arise mid-
month. Surveillance measures under consideration were derived
from the literature about recommended procedures and included:
chest X-ray (CXR), chest computed tomography (CT) scan,
abdominal and/or pelvic CT scan, abdominal ultrasound (US),
head CT scan, head magnetic resonance imaging (MRI), liver
enzymes and/or lactate dehydrogenase levels, and complete
blood count (CBC) (Brozena et al, 1990; Ross, 1996; Brochez
et al, 2000; Olson et al, 2000; Virgo et al, 2000; Sober et al, 2001;
Bishop et al, 2002). Abdominal and pelvic CT scans were included
in the same category because either abdominal or pelvic CT
scanning may have been coded for only one procedure. The
Appendix lists the specific ICD-9-CM and Current Procedure
Terminology 4 (CPT-4) procedure codes used to capture these
surveillance tests.
Because in practice a follow-up visit, including skin examination
is the most common form of surveillance for melanoma patients,
we developed two algorithms to identify follow-up visits that
included skin examination. The first algorithm (‘‘sensitive follow-up
visit’’) included: encounters with a dermatologist, medical oncol-
ogist, surgical oncologist, or gynecologic oncologist, or any skin-
specific diagnosis or CPT-4 procedure indicating that their skin
was examined (Appendix). A second, less sensitive, but more
specific algorithm (‘‘specific follow-up visit’’) included an encounter
with a dermatologist, medical oncologist, surgical oncologist, or
gynecologic oncologist or an evaluation and management CPT
code visit with a general practitioner, a family physician, an
internist, an obstetrics/gynecologist, or a plastic surgeon, a
geriatrician, a nurse practitioner together with an ICD-9-CM
diagnosis of nevus, malignant neoplasm of skin unknown behavior,
melanoma, skin screen, or scar (Appendix).
Analysis Using relevant ICD-9-CM and CPT-4 codes, we deter-
mined receipt of any of the surveillance tests during the follow-up
period. The proportions of patients undergoing one or more
surveillance tests of a certain type or skin examinations were
computed at the end of 2 y of surveillance using a Kaplan-Meier
actuarial analysis that takes into account variable length of follow-
up time due to different dates of diagnosis and censoring (Cox,
1972). For the group of patients undergoing at least one test, we
computed the mean number of surveillance tests performed.
Overall differences in the proportion of patients undergoing
each surveillance test were analyzed by patient characteristics
(gender, 5 y age increments), clinical characteristics (Breslow
depth and historic stage), and individual SEER registries (coded by
letter). These differences were assessed by the log-rank test,
which can also be viewed as a measure of the differences in time to
the first surveillance test. Median follow-up time was computed,
but mean rather than median time to first event was reported
because the distribution of censoring for most tests did not permit
computation of median time to event. Because certain SEER
geographic regions appeared consistently to have higher propor-
tions of individuals receiving procedures, we performed a post-hoc
analysis to assess whether this result could be due to chance
alone. For this analysis, for each surveillance procedure, we ranked
regions by the proportion of patients who were tested at the end of
2 y of surveillance. These ranks were then dichotomized for each
region into tests that were performed above median (rank 6 of 11 or
higher), or below median (rank 5 or lower). To test the null
hypothesis that there is no correlation (i.e., independence) for
surveillance procedures to be above or below the median in a
given region, an exact w2 test was performed to assess differences
in observed and expected counts or ranks in each region ranked
above or below 6. As this test was significant, we assessed
whether specific regions had an unusually small or large number of
surveillance procedures that were ranked above or below median
in testing by comparing it with a binomial distribution with n¼ 10
(the number of tests assessed) and probability centered at the 6/11
ranking cut-point.
Cox proportional hazards survival analysis was used to
determine the independent association of patient characteristics,
tumor characteristics, and SEER registry, with receipt of surveil-
lance procedure as the outcome (Cox, 1972). First order interac-
tions were assessed by graphical method, with possible interaction
terms entered into the model for backwards elimination with
a¼ 0.05 criterion for inclusion. Separate models were developed
for each surveillance procedure of interest. All analyses were
adjusted for age, gender, comorbid conditions, stage of disease,
Breslow depth of tumor, and census-level socioeconomic status as
these variables may influence surveillance procedure incidence.
Proportional hazards assumptions were evaluated and when
violated were corrected through inclusion of time-dependent
covariates.
Because of the moderately large sample size and multiple
comparisons, we regarded a two-sided significance test with
po0.01 to indicate statistical significance. All analysis were
performed using SAS software (version 8.2, SAS Institute, Cary,
North Carolina).
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